Latest News of SWTX
SpringWorks Therapeutics, Inc. (SWTX) Stock Price, News, Quote & History - Yahoo Finance
By Yahoo! Finance |
1 month ago
The FDA has granted priority review to SpringWorks Therapeutics' NDA for mirdametinib to treat NF1-PN. The PDUFA target action date is February 28, 2025, and the EU Marketing Authorization Application...